139 related articles for article (PubMed ID: 35254199)
1. Efficacy and safety of newly developed ganirelix acetate in infertile women for assisted reproductive technology: a prospective, randomised, controlled study.
Han EJ; Lyu SW; Kwak IP; Kwon H; Choi DH; Kim JY; Park HM; Kim JW; Chang EM; Lee HJ; Kim MK; Lee HN; Kim JY; Park S; Lee WS
J Obstet Gynaecol; 2022 Aug; 42(6):2197-2202. PubMed ID: 35254199
[TBL] [Abstract][Full Text] [Related]
2. Medroxyprogesterone Acetate versus Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surge in hyper-responder women undergoing controlled ovarian stimulation for IVF/ICSI Cycles.
Tandulwadkar S; Gupta S; Singh A; Mishra S; Singhania S
JBRA Assist Reprod; 2023 Mar; 27(1):15-19. PubMed ID: 35621299
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of the gonadotropin-releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer with recombinant follicle-stimulating hormone.
Moon SY; Ku SY; Kim SM; Jee BC; Suh CS; Choi YM; Kim JG; Kim SH
J Obstet Gynaecol Res; 2005 Jun; 31(3):227-35. PubMed ID: 15916659
[TBL] [Abstract][Full Text] [Related]
4. A premature luteinizing hormone surge without elevated progesterone levels has no adverse effect on cumulative live birth rate in patient undergoing a flexible GnRH antagonist protocol: a retrospective study.
Zhang Y; Xu Y; Yu J; Wang X; Xue Q; Shang J; Yang X; Shan X
J Ovarian Res; 2023 Jun; 16(1):119. PubMed ID: 37370146
[TBL] [Abstract][Full Text] [Related]
5. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.
Borm G; Mannaerts B
Hum Reprod; 2000 Jul; 15(7):1490-8. PubMed ID: 10875855
[TBL] [Abstract][Full Text] [Related]
6. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation.
European and Middle East Orgalutran Study Group
Hum Reprod; 2001 Apr; 16(4):644-51. PubMed ID: 11278211
[TBL] [Abstract][Full Text] [Related]
7. Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial.
Beguería R; García D; Vassena R; Rodríguez A
Hum Reprod; 2019 May; 34(5):872-880. PubMed ID: 30927417
[TBL] [Abstract][Full Text] [Related]
8. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
9. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial.
Dong J; Wang Y; Chai WR; Hong QQ; Wang NL; Sun LH; Long H; Wang L; Tian H; Lyu QF; Lu XF; Chen QJ; Kuang YP
BJOG; 2017 Jun; 124(7):1048-1055. PubMed ID: 28276192
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Luteinising Hormone Suppression in In Vitro Fertilisation Antagonist Cycles.
Goh JP; Lee JCS; Chan JKY; Allen JC; Ng XW; Nadarajah S; Phoon JWL; Liu S
Reprod Sci; 2021 Nov; 28(11):3164-3170. PubMed ID: 34076868
[TBL] [Abstract][Full Text] [Related]
11. Dual trigger with the combination of gonadotropin-releasing hormone agonist and standard dose of human chorionic gonadotropin improves
Mutlu I; Demirdag E; Cevher F; Erdem A; Erdem M
J Obstet Gynaecol; 2022 Jul; 42(5):1239-1244. PubMed ID: 34565274
[TBL] [Abstract][Full Text] [Related]
12. [Effects of cetrorelix versus ganirelix in gonadotropin-releasing hormone antagonist cycles for preventing premature luteinizing hormone surges and on clinical outcomes of IVF-ET cycles].
Zhang J; Zhou X; Chen Y; Zhang Q; Li Y; Zhe J; Chen X; Chen S
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Oct; 39(10):1207-1212. PubMed ID: 31801718
[TBL] [Abstract][Full Text] [Related]
13. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.
Fauser BC; de Jong D; Olivennes F; Wramsby H; Tay C; Itskovitz-Eldor J; van Hooren HG
J Clin Endocrinol Metab; 2002 Feb; 87(2):709-15. PubMed ID: 11836309
[TBL] [Abstract][Full Text] [Related]
14. Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies.
Wilcox J; Potter D; Moore M; Ferrande L; Kelly E;
Fertil Steril; 2005 Jul; 84(1):108-17. PubMed ID: 16009165
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial.
Wang Y; Kuang Y; Chen Q; Cai R
Trials; 2018 Aug; 19(1):455. PubMed ID: 30134964
[TBL] [Abstract][Full Text] [Related]
16. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
Itskovitz-Eldor J; Kol S; Mannaerts B
Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
[TBL] [Abstract][Full Text] [Related]
17. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon).
de Jong D; Macklon NS; Eijkemans MJ; Mannaerts BM; Coelingh Bennink HJ; Fauser BC;
Fertil Steril; 2001 Apr; 75(4):688-93. PubMed ID: 11287020
[TBL] [Abstract][Full Text] [Related]
19. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
[TBL] [Abstract][Full Text] [Related]
20. Use of gonadotrophin-releasing hormone agonists to trigger ovulation.
Tay CC
Hum Fertil (Camb); 2002 Feb; 5(1):G35-7; discussion G38-9, G41-8. PubMed ID: 11939159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
